Vince & Associates Clinical Research Begins Construction on $5 Million Expansion Project

FOR MORE INFORMATION: Bruce Copeland (913) 696-1601

(Overland Park, Kan., April 29, 2014) — Vince & Associates Clinical Research, a leading provider of comprehensive, early development clinical research services for the global biopharmaceutical industry, broke ground on a new $5 million expansion of its research campus.

Vince & Associates is recognized for its ability to rapidly and effectively recruit and retain both special patient populations and healthy normal volunteers in early phase clinical trials. The new building will house an expanded recruitment center that will support the demand for qualified subjects as well as benefit clients by further enhancing the company’s ability to recruit for complex early development clinical trials.

“Our effective recruitment and execution of complex early development trials stem from our extensive, therapeutically driven database. By consistently meeting our client’s enrollment milestones, we are able to reliably provide early efficacy data for our clients’ drug development decisions,” said Dr. Brad Vince, CEO and medical director of Vince & Associates Clinical Research.

Included in this new three-story building will be an advanced medical/surgical suite for specialized clinical trial procedures, such as endoscopies, biopsies and EEGs, as well as luxuriously designed research suites ideal for volunteers participating in overnight clinical trials.

A new, state-of-the-art pharmacy will provide additional capabilities for the extensive drug preparation methods conducted at Vince & Associates and will include an expanded USP 797 certified clean room that will exceed standards by maintaining an ISO Class V environment.

“The construction of this new three-story building will allow us to keep pace with demand from the global biopharmaceutical industry as well as provide a clear, strategic advantage for Vince & Associates in the conduct of complex clinical trials,” said Dr. Vince.

About Vince & Associates Clinical Research Vince & Associates Clinical Research has provided clinical research services to the biopharmaceutical industry for nearly 15 years. The research professionals at Vince & Associates are proud to be recognized in the industry as a “Center of Research Excellence.”

Vince & Associates currently operates a state-of-the-art, multimillion-dollar, 90-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This early development unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short- and long-term clinical trials. From the safety and security of the controlled access unit to the added features of a movie theater and game rooms, no detail has been overlooked.

About Altasciences Altasciences is the parent company of wholly owned subsidiaries Vince & Associates Clinical Research (Kansas, USA) and Algorithme Pharma (Quebec, Canada). Both organizations provide comprehensive early stage clinical services in Phase I/IIa, including the necessary support services in this critical stage of drug development.

More Information Additional background materials pertaining to Vince & Associates Clinical Research are located on the corporate website at

To our users and readers

Press Release Central has moved to a new server. What does this mean for you? Releases posted prior to March 1, 2012 have gone away, as has your old account registration info. Everyone will need to re-register for an account. We apologize for this inconvenience.

Want your event in our calendar?

Would you like your event published in The Kansas City Star? We’d be glad to consider it.

Enter your event


About Press Release Central

Press Release Central is Kansas City’s largest community site for press releases announcing news of all kinds: business, entertainment, sports and more. Releases stay for an extended period, so messages live a long life. And if you’re hunting for tips or information, just search to find news, names and subjects you might have missed.